BridgeBio Pharma, Inc. $BBIO Shares Newly Bought by Aberdeen Group plc

BridgeBio Pharma logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Aberdeen Group plc bought 301,848 BridgeBio Pharma shares in the third quarter, valued at about $19.9 million, representing roughly 0.15% of the company.
  • Institutional investors own 99.85% of BridgeBio shares. Analysts’ consensus rating is “Moderate Buy,” with an average price target of $104.42.
  • BridgeBio reported quarterly revenue of $353.17 million, up 192.6% year over year, and a loss of $0.42 per share—better than analysts’ expected loss of $0.54.
  • MarketBeat previews top five stocks to own in December.

Aberdeen Group plc purchased a new stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 301,848 shares of the company's stock, valued at approximately $19,862,000. Aberdeen Group plc owned approximately 0.15% of BridgeBio Pharma at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the stock. Jupiter Topco LLC purchased a new stake in BridgeBio Pharma in the 2nd quarter worth approximately $1,050,762,000. Janus Henderson Group PLC increased its position in shares of BridgeBio Pharma by 19.8% in the first quarter. Janus Henderson Group PLC now owns 13,179,013 shares of the company's stock valued at $978,608,000 after buying an additional 2,178,556 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new position in shares of BridgeBio Pharma during the 2nd quarter worth $145,663,000. Primecap Management Co. CA acquired a new position in shares of BridgeBio Pharma during the 2nd quarter worth $75,670,000. Finally, Squarepoint Ops LLC raised its stake in shares of BridgeBio Pharma by 114.2% during the 2nd quarter. Squarepoint Ops LLC now owns 1,191,732 shares of the company's stock worth $88,760,000 after buying an additional 635,408 shares during the last quarter. 99.85% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

BBIO has been the topic of several recent analyst reports. Barclays reduced their price objective on shares of BridgeBio Pharma from $157.00 to $156.00 and set an "overweight" rating on the stock in a research note on Wednesday, October 7th. HC Wainwright reiterated a "buy" rating on shares of BridgeBio Pharma in a research report on Tuesday, October 6th. Jefferies Financial Group reissued a "buy" rating on shares of BridgeBio Pharma in a research report on Monday, October 5th. Cantor Fitzgerald restated an "overweight" rating on shares of BridgeBio Pharma in a report on Monday, October 5th. Finally, Weiss Ratings downgraded shares of BridgeBio Pharma from a "sell (d)" rating to a "sell (d-)" rating in a research note on Friday, September 25th. Nineteen investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, BridgeBio Pharma has an average rating of "Moderate Buy" and an average price target of $104.42.

View Our Latest Analysis on BridgeBio Pharma

Insider Buying and Selling at BridgeBio Pharma

In other news, CAO Maricel Apuli sold 2,000 shares of the company's stock in a transaction dated Friday, October 30th. The shares were sold at an average price of $72.85, for a total transaction of $145,700.00. Following the completion of the transaction, the chief accounting officer owned 120,687 shares in the company, valued at approximately $8,792,047.95. This represents a 1.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Neil Kumar sold 10,000 shares of BridgeBio Pharma stock in a transaction that occurred on Thursday, September 17th. The shares were sold at an average price of $69.08, for a total value of $690,800.00. Following the sale, the chief executive officer directly owned 495,686 shares in the company, valued at approximately $34,241,988.88. This trade represents a 1.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 14.23% of the stock is owned by company insiders.

BridgeBio Pharma Stock Down 0.7%

BBIO opened at $76.80 on Wednesday. The company has a fifty day simple moving average of $70.07 and a 200 day simple moving average of $72.78. BridgeBio Pharma, Inc. has a twelve month low of $62.50 and a twelve month high of $93.42.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last issued its quarterly earnings data on Thursday, October 29th. The company reported ($0.42) EPS for the quarter, topping analysts' consensus estimates of ($0.54) by $0.12. The firm had revenue of $353.17 million during the quarter, compared to analyst estimates of $293.47 million. During the same quarter in the prior year, the firm earned ($0.95) EPS. The business's quarterly revenue was up 192.6% compared to the same quarter last year. Equities research analysts forecast that BridgeBio Pharma, Inc. will post -2.55 earnings per share for the current fiscal year.

BridgeBio Pharma Company Profile

(Free Report)

BridgeBio Pharma is a biopharmaceutical company that discovers, develops and commercializes medicines for genetic diseases and cancers. Founded in 2015, the company advances programs through a network of research and development subsidiaries focused on specific conditions and therapeutic areas. Its products include Attruby (acoramidis), an FDA-approved treatment for adults with transthyretin amyloid cardiomyopathy. BridgeBio also develops a pipeline of investigational therapies aimed at diseases with well-understood genetic causes, including rare and inherited conditions.

See Also

Want to see what other hedge funds are holding BBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report).

Institutional Ownership by Quarter for BridgeBio Pharma (NASDAQ:BBIO)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in BridgeBio Pharma Right Now?

Before you consider BridgeBio Pharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BridgeBio Pharma wasn't on the list.

While BridgeBio Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines